Page results
-
UCLH has declared a climate and health emergency and has published an action plan to reach net zero carbon dioxide emissions.
-
King Charles III and Queen Camilla met patients and families living with cancer to hear their hopes and fears as they received care at UCLH in London today.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
-
This information will give you an overview of BCG immunotherapy, how it is given and side effects it may cause.
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
-
UCLH will play a vital role in a new respiratory virus study.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology